Skip to content
Aminoscope
Head-to-head

GHRP-2 vs Sermorelin

Two different doors to the same growth-hormone pulse, a ghrelin-receptor agonist versus a GHRH analog. The gap that matters is selectivity and regulatory standing.

By Julian RothResearch & dataUpdated October 2026

Short answer

Both have human clinical data behind them, which makes the goal the real difference between GHRP-2 and sermorelin. For a reader focused on muscle, GHRP-2 is the relevant choice; sermorelin is marketed for GH deficiency. For GHRP-2, five days of daily injections in healthy men did not raise IGF-1, and the GH response faded.

GHRP-2

Pralmorelin

Clinical data

Genuinely raises GH (and is an approved diagnostic in Japan), but the same dose lifts cortisol, prolactin and appetite, and desensitizes — no anti-aging outcomes.

Full GHRP-2 evidence review

Sermorelin

Geref

Clinical data

A former FDA-approved GHRH analog (now compounded); real GH-axis data, no anti-aging outcome evidence.

Full Sermorelin evidence review

GHRP-2 vs Sermorelin: head to head

FDA status / approved use

GHRP-2

Approved in Japan only as a growth-hormone diagnostic; not FDA-approved; sold as gray-market research peptide

Sermorelin

Used for diagnosing and treating childhood GH deficiency; branded US injectable discontinued for commercial reasons
Marketed for

GHRP-2

Muscle, 'anti-aging'

Sermorelin

GH deficiency, 'anti-aging'
Outcome areas

GHRP-2

Muscle / strength / lean mass; Longevity / lifespan

Sermorelin

Longevity / lifespan
Evidence grade

GHRP-2

Clinical data

Sermorelin

Clinical data
How it works

GHRP-2

Activates the ghrelin receptor to trigger a pulse of growth hormone from the pituitary

Sermorelin

GHRH analog that prompts the pituitary to release the body's own growth hormone
Route and dosing

GHRP-2

Subcutaneous injection

Sermorelin

Injection
Headline human result

GHRP-2

Five days of daily injections in healthy men did not raise IGF-1, and the GH response faded

Sermorelin

IGF-1 rose from 159.5 to 239.0 ng/mL in 14 hypogonadal men on a GHRP/sermorelin combination (2017); no outcome trials
Strongest evidence

GHRP-2

Bowers, Endocrine 2001GHRP-2 evidence reviewPubMed 11322505

Sermorelin

BioDrugs review, 1999Sermorelin evidence reviewPubMed 18031173
Key safety signal

GHRP-2

Also raises cortisol, ACTH and prolactin and increases appetite

Sermorelin

GH-axis effects on glucose handling, fluid retention and joints; theoretical IGF-1 proliferative concerns
How it is obtained

GHRP-2

Sold gray-market as a research chemical; no approved or legitimately compounded human product

Sermorelin

Prescribed and dispensed by compounding pharmacies; legality varies by compound

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

Clinical data:
Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).

Our verdict

Sermorelin is the better-grounded of the two. It is a GHRH analog with a documented clinical record in the diagnosis and treatment of idiopathic growth-hormone deficiency in children; the branded injectable was later discontinued for commercial reasons and it is now supplied largely through compounding pharmacies, which makes it a clinician's decision rather than a self-directed one. Its longevity use is still weak, resting on biomarker effects and a few targeted trials rather than healthspan outcomes. GHRP-2 works through the ghrelin receptor instead, is an approved diagnostic agent in Japan and not FDA-approved for body composition or anti-aging, and its GH pulse comes bundled: the same dose raises cortisol, ACTH and prolactin and increases appetite, the response attenuates with repeated dosing, and a five-day course in healthy men did not raise IGF-1. They have not been compared directly for any body-composition endpoint, and neither has outcome data for muscle or aging.

GHRP-2 fits if

GHRP-2 matters mainly to the reader who wants to understand a validated short-term probe of pituitary GH secretion, and why that diagnostic legitimacy does not transfer to daily use.

Sermorelin fits if

Sermorelin is the more relevant molecule for someone weighing a GHRH analog with an actual clinical history through a legitimate prescriber, provided the anti-aging claims are read as unproven.

GHRP-2 vs Sermorelin: common questions

Is either GHRP-2 or sermorelin FDA-approved?
No. GHRP-2 is approved in Japan only as a growth-hormone diagnostic; not FDA-approved; sold as gray-market research peptide. Sermorelin is used for diagnosing and treating childhood GH deficiency; branded US injectable discontinued for commercial reasons.
Which has stronger human evidence, GHRP-2 or sermorelin?
Neither clearly. Both have human clinical data. The key source for GHRP-2 is Bowers, Endocrine 2001; for sermorelin, it is BioDrugs review, 1999.
What are the main safety concerns with GHRP-2 and sermorelin?
GHRP-2 also raises cortisol, ACTH and prolactin and increases appetite. For sermorelin, watch for GH-axis effects on glucose handling, fluid retention and joints; theoretical IGF-1 proliferative concerns.

Key studies behind each

GHRP-2

  1. Arvat E, di Vito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R, Camanni F, Ghigo E. (1997). Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. PubMed 9285939
  2. Bowers CY, Granda-Ayala R. (2001). Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion. Endocrine. PubMed 11322505
  3. Chihara K, Shimatsu A, Hizuka N, Tanaka T, Seino Y, Katofor Y; KP-102 Study Group. (2007). A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur J Endocrinol. PubMed 17609397
  4. Laferrère B, Abraham C, Russell CD, Bowers CY. (2005). Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. PubMed 15699539

Sermorelin

  1. Prakash A, Goa KL. (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. PubMed 18031173
  2. Sigalos JT, Pastuszak AW, Allison A, et al. (2017). Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. Am J Mens Health. PubMed 28830317
  3. Sinha DK, Balasubramanian A, Tatem AJ, et al. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. PubMed 32257855
  4. Baker LD, Barsness SM, Borson S, et al. (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. PubMed 22869065

The full evidence reviews

Where to get it

Where to get peptide therapy

Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm GHRP-2 availability before ordering.

Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.

Compare all 204 peptide-therapy providers →

Provider reviews we publish: HealthSourceHelloWellnessHeva HealthImmortalsLumoraLunaRx

Related comparisons